Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • IHH Healthcare extends...

    IHH Healthcare extends acceptance period of enhanced revised offer for Fortis

    Written by Ruby Khatun Khatun Published On 2018-05-18T11:30:56+05:30  |  Updated On 18 May 2018 11:30 AM IST
    IHH Healthcare extends acceptance period of enhanced revised offer for Fortis

    New Delhi: Malaysian firm IHH Healthcare Berhard said it has extended the acceptance period of its enhanced revised proposal for Fortis Healthcare to May 29 after which it shall lapse.


    In a letter to the board of Fortis Healthcare, IHH Healthcare said it remains strongly committed to participate in bid for Fortis and is therefore very keen to understand the next steps the board is considering in the wake of the modified Manipal offer.


    "If there is indeed a new bid process that the Board is proposing to initiate, we would like to participate in such a process and request that we be kept informed of any developments regarding the same," IHH Healthcare MD and CEO Tan See Leng said in the letter.


    "We fully respect any such process that is run by the board and reiterate that we wish to engage with the Board and the shareholders of Fortis in identifying a mutually-beneficial and optimal solution," he added.


    In light of the expiry of the company's enhanced revised proposal on May 15, 2018, it extended the acceptance period of the same until May 29, 2018, after which it shall lapse, the letter said.


    The letter, however, emphasized that the enhanced revised proposal by IHH must be accepted in its entirety and cannot be accepted together or in conjunction with any other investment proposal from any third party.


    IHH Healthcare had increased its offer to directly invest in Fortis Healthcare at Rs 175 per share on May 1. It had initially made a non-binding offer to invest in Fortis at Rs 160 per share.


    IHH had on April 24, revised it to binding offer to immediately infuse Rs 650 crore by way of a preferential issue and allotment of equity shares at Rs 160 per share in FHL as part of an overall proposal to invest Rs 4,000 crore.


    Earlier this week, Manipal-TPG combine revised their offer for the cash-strapped healthcare chain with a proposal to invest in the company at Rs 180 per share, thereby increasing valuation of the company to Rs 9,403 crore.


    As many as five suitors were in the race for Fortis but after the company's board decided to evaluate only binding offers, Malaysias IHH Healthcare Berhad, Munjal-Burmans, Manipal-TPG and KKR-backed Radiant Life Care put in their bids.


    The fifth bidder, Fosun Health Holdings, an arm of Fosun International, which made a non-binding proposal to invest a total of USD 350 million (over Rs 2,295 crore) at a price up to Rs 156 per share, had not revised its offer.

    acceptance periodenhanced revised offerextendsFortisFortis HealthcareIHHIHH HealthcareManipalTan See LengTPG
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok